Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 4/20 | 0.37 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.36 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | PLK4 | O00444 | 1/20 | 0.32 |
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.32 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.32 |
| ▸ | ABL1 | P00519 | 1/20 | 0.32 |
| ▸ | LCK | P06239 | 1/20 | 0.32 |
| ▸ | CSF1R | P07333 | 1/20 | 0.32 |
| ▸ | RET | P07949 | 1/20 | 0.32 |
| ▸ | MET | P08581 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13693080 | 0.80 | PER2 (0.41) | DPP4P2RX7KAT2BACKR3KDM4E | |
| SCHEMBL12142180 | 0.75 | DRD4 (0.43) | — | |
| SCHEMBL22623893 | 0.75 | HDAC1 (0.44) | ALDH1A1L3MBTL1POLB | |
| SCHEMBL12142175 | 0.74 | MAPT (0.53) | P2RX7KDM4ETDP1ALDH1A1L3MBTL1 | |
| SCHEMBL20034984 | 0.70 | PIK3CD (0.34) | — | |
| SCHEMBL14749921 | 0.68 | PIK3CD (0.35) | L3MBTL1 | |
| SCHEMBL17517145 | 0.68 | PIK3CD (0.35) | L3MBTL1 | |
| SCHEMBL15199072 | 0.67 | PER2 (0.35) | DPP4 | |
| SCHEMBL12326910 | 0.63 | DPP4 (0.39) | DPP4P2RX7ACKR3KDM4ETSHR | |
| SCHEMBL8521171 | 0.61 | SIGMAR1 (0.50) | TDP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8067589-B2 | Heterocyclic compounds useful in treating diseases and conditions | PFIZER INC (US) | 2011-11-29 | — | — | US | disclosed |
| US-8067589-B2 | Heterocyclic compounds useful in treating diseases and conditions | PFIZER INC (US) | 2011-11-29 | — | — | US | disclosed |
| US-20090281125-A1 | Heterocyclic Compounds Useful in Treating Diseases and Conditions | BLAKE TANISHA D | 2009-11-12 | — | — | US | disclosed |
| US-20090281125-A1 | Heterocyclic Compounds Useful in Treating Diseases and Conditions | BLAKE TANISHA D | 2009-11-12 | — | — | US | disclosed |
| US-7582643-B2 | Heterocyclic compounds useful in treating diseases and conditions | PFIZER INC (US) | 2009-09-01 | — | — | US | disclosed |
| US-20080207651-A1 | Heterocyclic compounds useful in treating diseases and conditions | BLAKE TANISHA D | 2008-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281125-A1 | Heterocyclic Compounds Useful in Treating Diseases and Conditions | CYP11B2, CYP11B1, LTC4S | DPP4 967/4885P2RX7 1177/4885KAT2B 1301/4885 |
| US-20080207651-A1 | Heterocyclic compounds useful in treating diseases and conditions | CYP11B2, CYP11B1, LTC4S | DPP4 967/4885P2RX7 1177/4885KAT2B 1301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.